FY2026 EPS Forecast for Krystal Biotech Increased by Analyst

Krystal Biotech, Inc. (NASDAQ:KRYS) – Investment analysts at HC Wainwright increased their FY2026 earnings estimates for Krystal Biotech in a research note issued to investors on Monday, November 4th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of $7.02 per share for the year, up from their prior forecast of $6.47. HC Wainwright has a “Buy” rating and a $221.00 price objective on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $2.88 per share.

Several other research firms also recently issued reports on KRYS. Citigroup boosted their price target on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday. Chardan Capital upped their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Stifel Nicolaus raised their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Evercore ISI boosted their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a report on Monday, August 12th. Finally, William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $197.00.

Krystal Biotech Trading Up 5.0 %

Krystal Biotech stock opened at $183.09 on Wednesday. The company has a market capitalization of $5.26 billion, a price-to-earnings ratio of 103.44 and a beta of 0.82. Krystal Biotech has a 12 month low of $93.95 and a 12 month high of $219.34. The stock’s 50 day moving average is $181.39 and its 200-day moving average is $180.25.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. The business had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. Krystal Biotech’s quarterly revenue was up 879.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.67) EPS.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of KRYS. Jamison Private Wealth Management Inc. bought a new position in Krystal Biotech in the 2nd quarter valued at approximately $28,000. GAMMA Investing LLC boosted its holdings in shares of Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after acquiring an additional 93 shares in the last quarter. Key Financial Inc bought a new stake in Krystal Biotech during the 2nd quarter worth $28,000. Blue Trust Inc. grew its position in Krystal Biotech by 2,328.6% during the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after acquiring an additional 163 shares during the last quarter. Finally, Values First Advisors Inc. acquired a new position in Krystal Biotech in the 3rd quarter worth about $53,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).